In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Building A Company That Challenges The Conventions Of Surgical Robotics

Executive Summary

Per Vegard Nerseth is at the helm of CMR Surgical and hopes to transform surgery for good through the widespread introduction of surgical robotics.

You may also be interested in...



CMR Surgical Closes SoftBank-Led Funding Round Worth $600M

CMR Surgical has raised $600m to globally commercialize its Versius surgical robotics platform.

Exec Chat: Rapid Expansion For CMR Surgical As It Launches Robotic System In More Countries

Per Vegard Nerseth, CEO of private surgical robotics company CMR Surgical, spoke to Medtech Insight about the UK firm's plans to democratize robot-assisted surgery.

Minute Insight: SonALAsense MR-Guided Ultrasound Drug-Device Combo Trials Get Green Light

SonALAsense has received Safe to Proceed letters from the FDA to begin trials of its ultrasound-activated cancer killing drug.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

IV125115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel